Skip to content
April 29, 2026

The SUM Cancer Cell Line Knowledge Base (SLKBase)

Using functional genomics to navigate critical pathways for growth and survival of breast cancer cells

  • Welcome Cancer Researchers!
    • Contact Us
    • Password Reset
  • SLKBase!
    • Key features of this cell line panel
    • Why is it important to have a breast cancer cell line knowledge base?
    • The Omic data sets that were used to develop the SLKBase
    • SLKBase Functional Cancer Cell Line Genomics by Sextant Oncology LLC
    • Functional Druggable Signatures for the SUM cell lines
    • See what we’re working on to make the Knowledge Base better
    • SUM Cell Lines Gateway Page
    • About Steve Ethier
    • Blog posts on the SUM breast cancer cell lines
    • YouTube Video and Data Download Center
    • SUM line media and protocols
      • SUM Cell lines culture media
      • Media components
      • How to prepare materials for growth media
    • Please join the SLKBase email list on MailChimp
  • Gateway to the SUM Breast Cancer Cell Lines
    • SUM-44 Home
      • The Story of the SUM-44PE cell line
      • Bibliography of published papers in which SUM-44 cells were used
      • Narrative summary of molecular and cellular characteristics of the SUM-44PE cells
      • Oncogene Signatures for SUM-44PE cells
      • The KEGG canonical pathways enriched with data from our genome-scale shRNA screen in SUM-44 cells
        • Cell Cycle Pathway
        • PI3’K/AKT pathway
        • WNT Pathway
        • Hippo Pathway
        • MAPK Signaling
        • Apoptosis
        • Cytokine-Cytokine Receptor Interaction
        • ECM Receptor interaction
      • SUM-44 cells: Functional-druggable signature
      • Drug Sensitivity Data for functional-druggable targets of SUM-44 cells
        • SUM-44: Sensitivity to Navitoclax
        • SUM-44: Sensitivity to Palbociclib
        • SUM-44: Sensitivity to the PIK3CD inhibitor, Idelalisib
      • STR Profile for SUM-44 cells
    • SUM-52 Home
      • Derivation of the SUM-52PE breast cancer cell line
      • Bibliography of published papers in which SUM-52 cells were used
      • Narrative Summary of the SUM-52PE cell line
      • The Oncogenes of the SUM-52PE breast cancer cell line
        • SUM-52 genes that are amplified, overexpressed and were hits in the RNAi screen (functional oncogenes)
        • SUM-52 functional oncogene signature
      • The KEGG canonical pathways enriched with data from our genome-scale shRNA screen with SUM-52 cells
        • SUM-52 Cell Cycle pathway
        • SUM-52 PI3’K/AKT pathway
        • SUM-52 WNT pathway
        • SUM-52 Hippo Pathway
        • SUM-52 Apoptosis
        • SUM-52 MAPK signaling
        • SUM-52 ECM-Receptor Interaction
        • SUM-52 Cytokine-Cytokine Receptor Interaction
        • SUM-52 mTOR Pathway
        • SUM-52 Breast Cancer Pathway
        • SUM-52 Signaling Pathways Regulating Pluripotency of Stem Cells
      • SUM-52 Cells: Functional Druggable Signature
        • Drug sensitivities for SUM-52’s functional-druggable oncogenes
      • SUM-52 Differential drug sensitivity data
    • SUM-102 Home
      • Characteristics of the patient specimen from which SUM-102 was derived
      • SUM-102 Bibliography
      • The KEGG canonical pathways enriched with data from our genome-scale shRNA screen
        • SUM-102 Cell Cycle Pathway
        • SUM-102 ERBB Signaling
        • SUM-102 Apoptosis signalig
        • SUM-102 Jak-STAT pathway
        • SUM-102 MAPK signaling
        • SUM-102 mTOR signaling
        • SUM-102 PI3’K/AKT signaling
        • SUM-102 Focal Adhesion Signaling
        • SUM-102 ECM-Receptor Interaction
      • Narrative Summary of the SUM-102 Cell Line
      • The Candidate Oncogene Signature for SUM-159 cells.
      • SUM-102 cells: Functional-druggable Signature
      • STR Profile for SUM-102 cells
    • SUM-149 Home
      • Characteristics of the patient from which SUM-149PT was derived
      • SUM-149 Bibliography
      • Narrative Summary of the SUM-149 Cell Line
      • Functional amplified oncogenes in SUM-149PT cells
      • Mutational Oncogene Signature of SUM-149PT cells
      • KEGG canonical pathways enriched with data from the genome scale shRNA screen
        • SUM-149 PT Cell Cycle
        • SUM-149PT PI3’K/AKT Signaling
        • SUM-149PT mTOR signaling
        • SUM-149 PT ERBB Signaling Pathway
        • SUM-149PT MAPK Signaling
        • SUM-149PT WNT Signaling
        • SUM-149PT Apoptosis signaling
      • SUM-149 Cells: Functional-druggable Signature
      • SUM-149 Differential Drug Sensitivity Data
    • SUM-159 Home
      • Characteristics of the patient from which SUM-159 was derived
      • SUM-159 Bibliography
      • The oncogenes of the SUM-159 cell line
      • The KEGG canonical pathways enriched with data from our genome-scale shRNA screen
        • Signaling pathways regulating pluripotency in cancer
        • SUM-159 WNT signaling
        • SUM-159 PI3’K/AKT signaling
        • SUM-159 MAPK signaling
        • SUM-159 Hippo Signaling
        • SUM-159 Cell Cycle
      • SUM-159 cells: Functional-druggable Signature
      • SUM-159 Differential Drug Sensitivity Data
    • SUM-185PE Home
      • Derivation of the SUM-185PE cell line
      • SUM-185PE Bibliograpy
      • Narrative Summary of the SUM-185PE cell line
      • SUM-185 Oncogene Signatures
      • KEGG pathways enriched with screen hit data for SUM-185
        • SUM-185 Cell Cycle Pathway
        • SUM-185PE PI3’kinase/AKT pathway
        • SUM-185 Hippo Signaling
        • SUM-185 MAPK pathway: Genes that were hits in the screen
        • SUM-185 TGF-Beta signaling
        • SUM-185 WNT signaling
        • SUM-185PE Apoptosis
        • SUM-185 FoxO signaling
        • SUM-185PE Focal Adhesion Signaling
      • SUM-185 cells: Functional-druggable signature
      • SUM-185 Differential Drug Sensitivity (uM)
    • SUM-190 Home
      • Characteristics of the patient from which SUM-190 was derived and derivation of the cell line
      • SUM-190 Bibliography
      • The SUM-190 Oncogene Signatures
      • The point mutational oncogene signature of SUM-190
      • Narrative Summary of the SUM-190 Cell Line
      • The KEGG canonical pathways enriched with data from our genome-scale shRNA screen
        • SUM-190 Cell Cycle Pathway
        • SUM-190 PI3’K/AKT Pathway
        • SUM-190 Phosphatidylinositol Signaling System
        • SUM-190 mTOR Signaling
        • SUM-190 ERBB Signaling Pathway
        • SUM-190 MAPK Signaling Pathway
        • SUM-190 WNT Signaling
        • SUM-190 Apoptosis Signaling Pathway
        • SUM-190 ECM Receptor Interaction
        • SUM-190 Hippo Signaling
      • SUM-190 Cells: Functional-druggable Signature
    • SUM-225 Home
      • SUM-225 Characteristics of the patient from which SUM-225 was derived
      • SUM-225 Bibliograpy
      • SUM-225 Oncogene Signatures
      • SUM-225 point mutational oncogene signature
      • SUM-225 KEGG pathways enriched with data from the genome-scale shRNA screen
        • SUM-225 Cell cycle
        • SUM-225 ERBB signaling
        • SUM-225 PI3’K/AKT signaling
        • SUM-225 MAPK signaling
        • SUM-225 Apoptosis signaling
        • SUM-225 FOXO signaling
        • SUM-225 Hedgehog Signaling
        • SUM-225 HIF-1 Signaling
        • SUM-225 TGF-beta signaling
        • SUM-225 RAS signaling
        • SUM-225 mTOR signaling
        • SUM-225 WNT signaling
        • SUM-225 Hippo Signaling
        • SUM-225 Signaling pathways regulating pluripotency in stem cells
      • SUM-225 Cells: Functional-druggable Signature
      • STR Profile for SUM-225 cells
      • SUM225 differential drug sensitivity data
    • SUM-229 Home
      • Derivation of the SUM-229 cell line
      • SUM-229 Bibliography
      • The Oncogene Signatures for the SUM-229 cell line
      • Narrative Summary of the SUM-229 cell line
      • The KEGG canonical pathways enriched with data from our genome-scale shRNA screen of SUM-229
        • SUM-229 Cell Cycle
        • SUM-229 PI3’K/AKT signaling
        • SUM-229 MAPK Signaling
        • SUM-229 Apoptosis Signaling
        • SUM-229 TGF-beta signaling
        • SUM-229 WNT Signaling
        • SUM-229 Phosphatidylinositol signaling system
        • SUM-229 Hippo Signaling
        • SUM-229 RAS Signaling
      • SUM-229 Cells: Functional-druggable Signature
    • SUM-1315 Home
      • Derivation of the SUM-1315 breast cancer cell line
      • SUM-1315 Bibliograpy
      • The Oncogene Signatures of the SUM-1315 cell line
      • The KEGG canonical pathways enriched with data from our genome-scale shRNA screen
        • SUM-1315 Cell Cycle
        • SUM-1315 Cell Adhesion Molecules
        • SUM-1315 FOXO Signaling
        • SUM-1315 Hippo Signaling
        • SUM-1315 WNT Signaling
        • SUM-1315 Signaling pathways regulating pluripotency in stem cells
        • SUM-1315 PI3’K/AKT Signaling
        • SUM-1315 TGF-beta Signaling
      • SUM1315 cells: Functional-druggable signature
      • SUM-1315 Differential Drug Sensitivity Data (uM)
    • Data mining tools for the SUM breast cancer cell lines
      • Oncogene Signature Tool
      • SUM-line KEGG pathway engine
        • KEGG Pathway Engine tutorial
      • KEGG Pathway Analysis tool:
      • KEGG Pathway Druggable Functional Pathway Analysis:
      • Sum Line Gene Query
      • Proteomics and Phophoproteomic data for the SUM breast cancer cell line
      • Proteomic analysis of the SUM cell lines. Graphs of key proteins
        • Unsupervised cluster analysis of the RPPA results derived from the SUM cell lines
        • ER, AR, and GATA 3 expression in the SUM lines
        • AKT-pS308, AKT-pT473, PTEN, RPS6, RPS6-pS235, RPS6-pS240
        • Annexin1, Notch1, Taz, Mct4, Sox2, Vhl-Eppk1
        • Bcl2, Bcl-xL, MCL1, Bid, Bim
        • beta-catenin, p53, c-Myc, Brd4, Prex1
        • Caveolin1, connexin43, E-cadherin, EMA, FN1
        • CyclinD1, CyclinD3, GAB2
        • Dusp4, p16ink4, Pai-1, p21, Rad51, Fasn
        • Her2, HER2 (minus amplified cell lines), Her3, Egfr
        • PKCa, Syk, Axl
        • Src, Src-pY416, Src-pY527, p38Mapk, Shc-pY317, Shp2 pY542
        • Vegfr2, Igfbp2, Ndrg1, Met-pY1234
    • HOW TO ACQUIRE THE SUM BREAST CANCER CELL LINES
      • Why it is important for investigators to obtain cancer cell lines from a reputable source
  • Gateway to 40 Breast Cancer Cell Lines
    • Data Mining Tools for the Additional Breast Cancer Cell Lines
      • Oncogene Signatures Tool
      • KEGG Pathway Engine for use with CRISPR data, RNAi data, or gene expression data
      • Gene Query
      • Breast Cancer Cell Line Druggable Signature Tool
    • AU565 Breast Cancer Cell Line
    • The BT549 breast cancer cell line
    • The CAL51 Breast Cancer Cell Line
    • The CAMA1 Breast Cancer Cell Line
    • The EFM19 Breast Cancer Cell Line
    • The DU4475 Breast Cancer Cell Line
    • The BT20 Breast Cancer Cell Line
    • The CAL120 Breast Cancer Cell line
    • The HCC70 Breast Cancer Cell Line
    • The HCC202 Breast Cancer Cell Line
    • The HCC1143 Human Breast Cancer Cell Line
    • The HCC1187 Breast Cancer Cell Line
    • The HCC1395 Breast Cancer Cell Line
    • The HCC1419 Breast Cancer Cell Line
    • The HCC1428 Breast Cancer Cell Line
    • The HCC1500 Breast Cancer Cell Line
    • The HCC1569 Breast Cancer Cell Line
    • The HCC1806 Breast Cancer Cell Line
    • The HCC1937 Breast Cancer Cell Line
    • The HCC1954 Breast Cancer Cell Line
    • The HCC2218 Breast cancer cell line
    • The HMC18 breast cancer cell line
    • The Hs578T breast cancer cell line
    • The JIMT1 Human breast cancer cell line
    • The KPL1 Breast Cancer Cell Line
    • The MCF-7 Human Breast Cancer Cell Line
    • The MDA-MB-231 Breast Cancer Cell Line
    • The MDA-MB-468 breast cancer cell line
    • The MDA-MB-134VI breast cancer cell line
    • The MDA-MB-175VII breast cancer cell line
    • The MDA-MB-157 breast cancer cell line
    • The MDA-MB-361 Breast Cancer Cell Line
    • The MDA-MB-415 breast cancer cell line
    • The MDA-MB-436 breast cancer cell line
    • The MDA-MB-453 breast cancer cell line
    • The SKBR3 breast cancer cell line
    • The T47D breast cancer cell line
    • The UACC812 breast cancer cell line
    • The ZR7530 breast cancer cell line
    • The ZR751 breast cancer cell line
  • Data Mining Tools for all cancer cell lines
    • Gene Query, Oncogene Signature, and Genomic analysis app for all cancer cell lines
    • Expanded Cell Line Gene Query
    • Cancer Cell Line Oncogene Signature and Drug Sensitivity page
    • KEGG Pathway app for gene expression and gene essentiality data
  • The SLKBase BLOG!
  • Sextant Oncology LLC
Main Menu

Drug Sensitivity Data for functional-druggable targets of SUM-44 cells

Navitoclax

Palbociclib

Idelalisib

Copyright © 2026 The SUM Cancer Cell Line Knowledge Base (SLKBase).
Powered by WordPress and HitMag.
Verified by MonsterInsights